Submitted by Anonymous (not verified) on 31 July 2025 - 14:12
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 13, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 13, Status: Authorised